• 1. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
• 2. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 3. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 4. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 5. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Phenylpyrazoles
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Pyrazoles Phenylpyrazoles

Introduction to 3-(4-Bromophenyl)-1H-pyrazole-4-carbaldehyde (CAS No. 350997-68-1)

3-(4-Bromophenyl)-1H-pyrazole-4-carbaldehyde, identified by the CAS number 350997-68-1, is a significant compound in the realm of pharmaceutical chemistry and medicinal research. This heterocyclic aldehyde derivative has garnered attention due to its versatile structural framework, which makes it a valuable scaffold for the development of novel bioactive molecules. The presence of both bromine and aldehyde functional groups in its molecular structure enhances its reactivity, enabling diverse chemical transformations that are pivotal for drug discovery processes.

The compound belongs to the pyrazole class of heterocycles, which are well-documented for their broad spectrum of biological activities. Pyrazoles have been extensively studied for their potential in treating various diseases, including inflammation, cancer, and infectious disorders. The introduction of a bromine substituent at the 4-position of the phenyl ring and an aldehyde group at the 4-position of the pyrazole ring in 3-(4-Bromophenyl)-1H-pyrazole-4-carbaldehyde introduces unique pharmacophoric features that can modulate receptor interactions and metabolic pathways.

Recent advancements in medicinal chemistry have highlighted the importance of pyrazole derivatives in developing targeted therapies. The structural motif of 3-(4-Bromophenyl)-1H-pyrazole-4-carbaldehyde allows for selective binding to biological targets, making it a promising candidate for further pharmacological exploration. For instance, studies have demonstrated that pyrazole-based compounds can interact with enzymes and receptors involved in disease mechanisms, thereby serving as potential leads for drug development.

In the context of modern drug discovery, the reactivity of 3-(4-Bromophenyl)-1H-pyrazole-4-carbaldehyde is particularly noteworthy. The aldehyde group can participate in condensation reactions with various nucleophiles, such as amines and hydrazines, to form Schiff bases or hydrazones. These derivatives have shown promise in preclinical studies as inhibitors or modulators of key biological pathways. Additionally, the bromine atom provides a handle for further functionalization via cross-coupling reactions like Suzuki or Buchwald-Hartwig couplings, enabling the construction of more complex molecular architectures.

One of the most compelling aspects of 3-(4-Bromophenyl)-1H-pyrazole-4-carbaldehyde is its potential application in oncology research. Pyrazole derivatives have been implicated in disrupting cancer cell proliferation and inducing apoptosis. The specific arrangement of substituents in this compound may enhance its ability to interact with oncogenic proteins or enzymes, offering a novel approach to cancer therapy. Preliminary computational studies suggest that modifications to the phenyl ring or the pyrazole core could fine-tune its binding affinity to specific targets, paving the way for structure-activity relationship (SAR) studies.

The synthesis of 3-(4-Bromophenyl)-1H-pyrazole-4-carbaldehyde involves multi-step organic transformations that highlight its synthetic utility. Starting from readily available precursors such as 4-bromobenzaldehyde and hydrazine hydrate, the pyrazole core can be constructed through condensation reactions followed by bromination and selective functional group manipulation. This synthetic accessibility makes it an attractive building block for medicinal chemists seeking to explore new chemical spaces.

Recent publications have begun to explore the pharmacological profile of 3-(4-Bromophenyl)-1H-pyrazole-4-carbaldehyde and its derivatives. In vitro assays have shown that certain pyrazole-based compounds exhibit inhibitory activity against enzymes such as cyclooxygenase (COX) and lipoxygenase (LOX), which are implicated in inflammation and pain pathways. Moreover, structural analogs have demonstrated antiviral properties by interfering with viral replication mechanisms. These findings underscore the therapeutic potential of this class of compounds.

The role of computational chemistry in optimizing 3-(4-Bromophenyl)-1H-pyrazole-4-carbaldehyde derivatives cannot be overstated. Molecular modeling techniques allow researchers to predict binding affinities, identify key interaction sites, and design analogs with improved pharmacokinetic profiles. By integrating experimental data with computational insights, scientists can accelerate the drug discovery pipeline and reduce attrition rates associated with lead optimization.

In conclusion,3-(4-Bromophenyl)-1H-pyrazole-4-carbaldehyde (CAS No. 350997-68-1) represents a fascinating compound with significant implications for pharmaceutical research. Its unique structural features and reactivity make it a valuable tool for developing novel therapeutic agents targeting various diseases. As research continues to uncover new biological functions and synthetic strategies for pyrazole derivatives,3-(4-Bromophenyl)-1H-pyrazole-4-carbaldehyde is poised to play a crucial role in shaping future advancements in medicinal chemistry.

• 350988-62-4(3-(4-methylphenyl)-1H-pyrazole-4-carbaldehyde)
• 306936-57-2(3-(4-Fluorophenyl)-1H-pyrazole-4-carbaldehyde)
• 26033-20-5(3-Phenyl-1H-pyrazole-4-carbaldehyde)
• 101563-75-1(6-methyl-3-(4-methylphenyl)-4-Pyridazinecarboxaldehyde)
• 879996-70-0(3-(3-Bromophenyl)-1H-pyrazole-4-carboxylic acid)
• 618383-49-6(3-(4-Bromophenyl)-1H-pyrazole-4-carboxylic acid)
• 350999-89-2(3-(4-ethylphenyl)-1H-pyrazole-4-carbaldehyde)
• 1150163-77-1(Methyl 3-(4-bromophenyl)pyrazole-4-carboxylate)
• 100007-87-2(3-(4-bromophenyl)-1h-indeno[1,2-c]pyrazol-4-one)
• 720696-71-9(3-(2,5-Dimethylphenyl)-1H-pyrazole-4-carbaldehyde)